2014
Clinical cancer research: the past, present and the future
DeVita VT, Eggermont AM, Hellman S, Kerr DJ. Clinical cancer research: the past, present and the future. Nature Reviews Clinical Oncology 2014, 11: 663-669. PMID: 25245981, DOI: 10.1038/nrclinonc.2014.153.Peer-Reviewed Original Research
2010
Focus issue on biomarkers
Hutchinson L, DeVita V. Focus issue on biomarkers. Nature Reviews Clinical Oncology 2010, 7: 295-295. PMID: 20517335, DOI: 10.1038/nrclinonc.2010.70.Peer-Reviewed Original Research
1984
NIH conference. T-cell lymphoproliferative syndrome associated with human T-cell leukemia/lymphoma virus.
Broder S, Bunn P, Jaffe E, Blattner W, Gallo R, Wong-Staal F, Waldmann T, DeVita V. NIH conference. T-cell lymphoproliferative syndrome associated with human T-cell leukemia/lymphoma virus. Annals Of Internal Medicine 1984, 100: 543-57. PMID: 6322632, DOI: 10.7326/0003-4819-100-4-543.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAdultAnimalsCell Transformation, NeoplasticCell Transformation, ViralDeltaretrovirusFemaleHumansLeukemia, LymphoidLymph NodesLymphomaLymphoproliferative DisordersMaleMiddle AgedNeoplastic Cells, CirculatingPhenotypeSyndromeT-LymphocytesTumor Virus InfectionsConceptsHuman T-cell leukemia/lymphoma virusAdult T-cell leukemia/lymphomaT-cell leukemia/lymphomaT-cell tropicLeukemia/lymphomaImmunologic featuresOpportunistic infectionsLymphoproliferative disordersLymphoproliferative syndromeMolecular biologicRNA tumor virusesTumor virusVirusClasses of retrovirusesMajor advancesRetrovirusesHypercalcemia
1983
Progress in cancer management. Keynote address
Devita V. Progress in cancer management. Keynote address. Cancer 1983, 51: 2401-2409. PMID: 6342749, DOI: 10.1002/1097-0142(19830615)51:12+<2401::aid-cncr2820511302>3.0.co;2-7.Peer-Reviewed Original ResearchConceptsCancer managementUtility of radiotherapyUse of radiotherapyCancer cure ratesWorld War IIEradication of cancerManagement of cancerPrime therapeutic targetFirst chemotherapyNational Cancer ActBlood transfusionLocal recurrenceMedical oncologistsTreatment failureRecurrent cancerCure rateWar IIEffective treatmentTherapeutic targetPatientsRadiotherapySurgerySuch toxicitySerious cancersCancer
1982
Immunological and physiological responses to whole-body hyperthermia.
Bull J, Lees D, Schuette W, Smith R, Glatstein E, DeVita V. Immunological and physiological responses to whole-body hyperthermia. National Cancer Institute Monograph 1982, 61: 177-81. PMID: 7177176.Peer-Reviewed Original Research
1981
Current results of the screening program at the division of cancer treatment, national cancer institute
Goldin A, Venditti J, Macdonald J, Muggia F, Henney J, Devita V. Current results of the screening program at the division of cancer treatment, national cancer institute. European Journal Of Cancer 1981, 17: 129-142. PMID: 6894902, DOI: 10.1016/0014-2964(81)90027-x.Peer-Reviewed Original ResearchConceptsNational Cancer InstituteScreening programCancer treatmentClinical trialsCancer InstituteHuman tumorsProspective screening programInadequate clinical trialsCategories of drugsActivity of drugsRenal capsuleClinical testingPanel testingScreening panelNew synthetic compoundsClinical interestNew drugsDrugsSubcutaneous modelTreatmentTumorsAntitumor agentsTrialsPotential usefulnessDefinitive answerAnimal toxicology for early clinical trials with anticancer agents.
Rozencweig M, Von Hoff D, Staquet M, Schein P, Penta J, Goldin A, Muggia F, Freireich E, DeVita V. Animal toxicology for early clinical trials with anticancer agents. American Journal Of Clinical Oncology 1981, 4: 21-8. PMID: 6783332.Peer-Reviewed Original ResearchConceptsPhase I clinical trialEarly clinical trialsClinical trialsOrgan system toxicityStarting doseSystem toxicityChemotherapeutic agentsDose-escalation stepsCommon toxic effectsGastrointestinal intoleranceInitial doseClinical dataEscalation stepsAnimal findingsToxic doseToxic manifestationsIndividual drugsPredictive valueAnimal toxicologyMiceDoseIdentical scheduleLD10Acceptable dosesDogs
1979
Human models of human diseases; breast cancer and the lymphomas
Devita V. Human models of human diseases; breast cancer and the lymphomas. International Journal Of Radiation Oncology • Biology • Physics 1979, 5: 1855-1867. PMID: 393666, DOI: 10.1016/0360-3016(79)90571-6.Peer-Reviewed Original ResearchMultimodal primary cancer treatment (adjuvant chemotherapy): current results and future prospects.
Weiss R, DeVita V. Multimodal primary cancer treatment (adjuvant chemotherapy): current results and future prospects. Annals Of Internal Medicine 1979, 91: 251-60. PMID: 380437, DOI: 10.7326/0003-4819-91-2-251.Peer-Reviewed Original ResearchConceptsDisease-free survivalPrimary treatment programGroup of patientsAdvanced diseaseTherapy regimensPrimary lesionSurgical removalAdult malignanciesPalliative treatmentTreatment resultsClinical trialsHuman trialsCancer mortalityChemotherapyMalignancyTreatment programsTreatmentRegimensPatientsLesionsCancerCombination chemotherapy of acute leukemia and lymphoma
Lewis B, DeVita V. Combination chemotherapy of acute leukemia and lymphoma. Pharmacology & Therapeutics 1979, 7: 91-121. PMID: 392552, DOI: 10.1016/0163-7258(79)90026-3.Peer-Reviewed Original Research
1978
High volume intraperitoneal chemotherapy (“Belly bath”) for ovarian cancer
Jones R, Myers C, Guarino A, Dedrick R, Hubbard S, DeVita V. High volume intraperitoneal chemotherapy (“Belly bath”) for ovarian cancer. Cancer Chemotherapy And Pharmacology 1978, 1: 161-166. PMID: 373916, DOI: 10.1007/bf00253116.Peer-Reviewed Original ResearchConceptsOvarian cancerIntraperitoneal chemotherapyPhase I clinical trialAdvanced stage diseaseIntraperitoneal fluid volumeIntraperitoneal methotrexateComplete remissionTreatment modalitiesPharmacologic principlesClinical trialsPeritoneal cavityTherapeutic effectivenessChemotherapyPharmacokinetic modelingDialysis fluidToxicologic studiesCancerFluid volumeDrug distributionRational chemotherapyFurther investigationRemissionPatientsMethotrexatePharmacokineticsThe Evolution of Therapeutic Research in Cancer
DeVita V. The Evolution of Therapeutic Research in Cancer. New England Journal Of Medicine 1978, 298: 907-910. PMID: 634335, DOI: 10.1056/nejm197804202981610.Peer-Reviewed Original ResearchNew Anticancer Drugs
Muggia F, Bono V, DeVita V. New Anticancer Drugs. Antibiotics And Chemotherapy 1978, 23: 42-49. PMID: 646328, DOI: 10.1159/000401470.Peer-Reviewed Original Research
1976
Chemotherapy research nurse.
Hubbard S, Devita V. Chemotherapy research nurse. American Journal Of Nursing 1976, 76: 560-5. PMID: 818899, DOI: 10.2307/3423770.Peer-Reviewed Original Research
1973
The Use of Drugs in Combination for the Treatment of Cancer — Rationale and Results
DeVita V, Schein P. The Use of Drugs in Combination for the Treatment of Cancer — Rationale and Results. New England Journal Of Medicine 1973, 288: 998-1006. PMID: 4348752, DOI: 10.1056/nejm197305102881905.Peer-Reviewed Original ResearchAnimalsAntineoplastic AgentsBreast NeoplasmsChildDose-Response Relationship, DrugDrug ResistanceDrug SynergismFemaleGastrointestinal NeoplasmsHodgkin DiseaseHumansLeukemia L1210Leukemia, LymphoidLeukemia, Myeloid, AcuteLymphomaMaleModels, BiologicalNeoplasmsNeuroblastomaRemission, SpontaneousTesticular NeoplasmsTime FactorsWilms Tumor
1972
THE EFFECT OF CHEMOTHERAPY ON THE GROWTH OF LEUKEMIA L1210 II. PERSISTENCE OF A NITROSOUREA‐INDUCED CHANGE IN THE GROWTH CHARACTERISTICS OF TRANSPLANT GENERATIONS
DeVita V, Bray D, Bostick F, Bagley C. THE EFFECT OF CHEMOTHERAPY ON THE GROWTH OF LEUKEMIA L1210 II. PERSISTENCE OF A NITROSOUREA‐INDUCED CHANGE IN THE GROWTH CHARACTERISTICS OF TRANSPLANT GENERATIONS. Cell Proliferation 1972, 5: 459-466. PMID: 4654583, DOI: 10.1111/j.1365-2184.1972.tb00384.x.Peer-Reviewed Original Research
1971
Chemotherapeutic implications of staging in Hodgkin's disease.
DeVita V, Carbone P. Chemotherapeutic implications of staging in Hodgkin's disease. Cancer Research 1971, 31: 1838-44. PMID: 4941352.Peer-Reviewed Original ResearchEffects of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU; NSC-79037) and its degradation products on progression of L1210 cells through the cell cycle.
Bray D, DeVita V, Adamson R, Oliverio V. Effects of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU; NSC-79037) and its degradation products on progression of L1210 cells through the cell cycle. Cancer Chemotherapy Reports 1971, 55: 215-20. PMID: 5115843.Peer-Reviewed Original Research
1970
Pneumocystis carinii Pneumonia.
Mansour N, DeVita V, Goodell B. Pneumocystis carinii Pneumonia. Annals Of Internal Medicine 1970, 73: 342-3. PMID: 5311515, DOI: 10.7326/0003-4819-73-2-342.Peer-Reviewed Original ResearchPentamidine: Clinical pharmacologic correlations in man and mice
Waalkes T, Denham C, DeVita V. Pentamidine: Clinical pharmacologic correlations in man and mice. Clinical Pharmacology & Therapeutics 1970, 11: 505-512. PMID: 5310706, DOI: 10.1002/cpt1970114505.Peer-Reviewed Original ResearchConceptsDiffuse interstitial pneumoniaInterstitial pneumoniaUrinary excretionPlasma levelsPneumocystis cariniiSingle intraperitoneal injectionTypes of pneumoniaDosage scheduleCancer patientsMalignant diseaseRenal abnormalitiesConcomitant useIntraperitoneal injectionIntramuscular administrationOrgan transplantationExcretion patternsPatientsPneumoniaPentamidineExcretionDrugsMenDiseaseMiceCarinii